Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Chani Stossel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4158-5549; OpenAlex author ID A5072940785. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Histologic spectrum of BRCA-associated pancreatic ductal adenocarcinoma: A descriptive morphologic study. Co-author DOI 10.1016/j.humpath.2026.106201↗
  2. A metabolic switch to the pentose-phosphate pathway induces radiation resistance in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2024.110606↗
  3. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05820-3↗
  4. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Co-author DOI 10.1158/2159-8290.cd-22-0412↗
  5. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  6. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  7. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  8. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. First author DOI 10.1002/ijc.31292↗
  9. Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease. First author DOI 10.18632/oncotarget.17253↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Talia Golan · 9 shared papers, 2017–2026 · strength 1.18
  2. Steve Gallinger · 6 shared papers, 2017–2023 · strength 0.54
  3. Gali Zabarsky Shasha · 1 shared paper, 2026 · strength 0.33
  4. Chen Mayer · 1 shared paper, 2026 · strength 0.33
  5. Raanan Berger · 4 shared papers, 2017–2023 · strength 0.33
  6. Grainne Mary O'Kane · 3 shared papers, 2020–2023 · strength 0.29
  7. Ariel Shimoni-Sebag · 1 shared paper, 2025 · strength 0.24
  8. Yaacov Richard Lawrence · 1 shared paper, 2025 · strength 0.24
  9. Faiyaz Notta · 2 shared papers, 2021–2023 · strength 0.22
  10. Rotem Karni · 2 shared papers, 2018–2023 · strength 0.20
  11. Spring Holter · 2 shared papers, 2020–2021 · strength 0.16
  12. Sandra Elisabeth Fischer · 2 shared papers, 2020–2021 · strength 0.16
  13. Ayelet Borgida · 2 shared papers, 2020–2021 · strength 0.16
  14. Robert C. Grant · 2 shared papers, 2020–2021 · strength 0.16
  15. Yifan Wang · 2 shared papers, 2020–2021 · strength 0.16
  16. Jennifer Jane Knox · 2 shared papers, 2020–2021 · strength 0.16
  17. George Zogopoulos · 2 shared papers, 2020–2021 · strength 0.16
  18. Ela Elyada · 1 shared paper, 2023 · strength 0.14
  19. Lewis C. Cantley · 1 shared paper, 2023 · strength 0.14
  20. Amina Jbara · 1 shared paper, 2023 · strength 0.14
  21. Adrian R. Krainer · 1 shared paper, 2023 · strength 0.14
  22. Hui‐Li Wong · 1 shared paper, 2021 · strength 0.09
  23. David F. Schaeffer · 1 shared paper, 2021 · strength 0.09
  24. Daniel John Renouf · 1 shared paper, 2021 · strength 0.09
  25. Zu‐Hua Gao · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.